会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 34. 发明申请
    • ANALOGUES OF N-ACETYLARDEEMIN, METHOD OF PREPARATION AND USES THEREOF
    • N-乙酰胺的类似物,其制备方法及其用途
    • WO1997018215A1
    • 1997-05-22
    • PCT/US1996019086
    • 1996-11-15
    • SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHTHE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFDANISHEFSKY, SamuelDEPEW, KristopherMARSDEN, Stephen, P.BORNMANN, WilliamWOO, Jonathan, C., G.CHOU, Ting-ChaoSCHKERYANTZ, JeffreyZATORSKI, Andrej
    • SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHTHE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF
    • C07D487/22
    • C07D487/22
    • The present invention provides a compound having structure (I) wherein R1, R6 and R7 are independently hydrogen, OH, NH2, SH, halogen, C1-C9 linear or branched chain alkyl, alkylmercapto, alkylamino, dialkylamino, alkoxy, phenyl, etc; wherein R0 and R2 are independently hydrogen, OH, linear or branched chain alkyl, -CR3R3-CH(O)CH2, -CR3R3-CH2CH3, -CR3R3-CH2CH2OH, -CR3R3-CH(OH)R4 or -CR3R3-CH=CHR4, wherein R3 and R4 are independently hydrogen, halogen, C1-C9 linear or branched chain alkyl, phenyl, etc; wherein R5 is hydrogen, C1-C9 linear or branched chain alkyl, phenyl, etc; an wherein R8 is hydrogen, C1-C9 linear or branched chain acyl, benzoyl, etc; with the proviso that (a) when R2 is -CR3R3-CH(O)CH2, -CR3R3-CH2CH3, -CR3R3-CH2CH2OH, -CR3R3-CH(OH)R4 or -CR3R3-CH=CHR4, then R0 is hydrogen; (b) when R0 is -CR3R3-CH(O)CH2, -CR3R3-CH2CH3, -CR3R3-CH2CH2OH, -CR3R3-CH(OH)R4 or -CR3R3-CH=CHR4, then R2 is OH; and (c) when (i) R0 or R2 is -CR3R3-CH=CHR4, (ii) R3 and R5 are CH3 and (iii) R4 is hydrogen, then R1, R6 and R7 are not all hydrogen. Also provided are related compounds and compositions, and methods of inhibiting the growth of multidrug resistant cells by means of MDR reversal, collateral sensitivity and quantitative synergism.
    • 本发明提供具有结构(I)的化合物,其中R 1,R 6和R 7独立地是氢,OH,NH 2,SH,卤素,C 1 -C 9直链或支链烷基,烷基巯基,烷基氨基,二烷基氨基,烷氧基,苯基等; 其中R 0和R 2独立地是氢,OH,直链或支链烷基,-CR 3 R 3 -CH(O)CH 2,-CR 3 R 3 -CH 2 CH 3,-CR 3 R 3 -CH 2 CH 2 OH,-CR 3 R 3 -CH(OH)R 4或-CR 3 R 3 -CH = CHR 4 其中R3和R4独立地是氢,卤素,C1-C9直链或支链烷基,苯基等; 其中R5是氢,C1-C9直链或支链烷基,苯基等; 其中R8是氢,C1-C9直链或支链酰基,苯甲酰基等; 条件是(a)当R 2为-CR 3 R 3 -CH(O)CH 2,-CR 3 R 3 -CH 2 CH 3,-CR 3 R 3 -CH 2 CH 2 OH,-CR 3 R 3 -CH(OH)R 4或-CR 3 R 3 -CH = CHR 4时,则R 0为氢; (b)当R 0是-CR 3 R 3 -CH(O)CH 2,-CR 3 R 3 -CH 2 CH 3,-CR 3 R 3 -CH 2 CH 2 OH,-CR 3 R 3 -CH(OH)R 4或-CR 3 R 3 -CH = CHR 4时,则R2是OH; 和(c)当(i)R 0或R 2为-CR 3 R 3 -CH = CHR 4时,(ⅱ)R 3和R 5为CH 3,(ⅲ)R 4为氢,则R 1,R 6和R 7不全为氢。 还提供了相关的化合物和组合物,以及通过MDR逆转,附着敏感性和定量协同作用抑制多药耐药细胞生长的方法。